Is U.S. drug market impregnable? Korean pharma & bio companies’ accelerated entry to the market
Becoming a global pharmaceutical company has become an topic of conversation among Korean pharmaceutical and biotechnology companies.
A barrier that pharmaceutical and biotechnology companies focusing on R&D consider to ascend a global pharmaceutical company is entry to the U.S. market. The U.S....
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.